Evotec OAI and Panacos Enter into Medicinal Chemistry Agreement to Design and Optimise Novel Anti-HIV Compounds

Hamburg, Germany | Oxfordshire, UK | Gaithersburg, MD, USA - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries, and Panacos Pharmaceuticals, Inc., a biotechnology company developing novel antiviral drugs for the treatment of Human Immunodeficiency Virus (HIV) infection and other major viral diseases, today announced that they have entered into a medicinal chemistry collaboration.
Panacos will take advantage of Evotec OAI's full range of state-of-the-art medicinal chemistry capabilities to identify drug candidates for the treatment of HIV infection.
Panacos recently announced that it has begun Phase 1 clinical trials of its small molecule, orally-available HIV drug candidate PA-457. PA-457 is the first in a new class of HIV drugs called Maturation Inhibitors, which have a  mechanism of action that differs from those of approved HIV drugs.  As a result, PA-457  exhibits potent activity against HIV strains resistant to current therapies, including inhibitors of reverse transcriptase and viral protease. The company also has an active discovery program focusing on the identification of small molecule inhibitors of viral fusion to human cells.
Mark Ashton, PhD, President Drug Discovery Services at Evotec OAI, said: "In working closely with the scientists at Panacos we were excited about the depth and level of scientific disease expertise. We are very pleased that Panacos has selected Evotec OAI as their partner of choice to support them in the advancement of this new class of compounds for HIV therapy."
"Evotec OAI is an industry leader in the supply of medicinal chemistry services to the biotechnology and pharmaceutical industries." commented Carl T. Wild, PhD, Chief Science Officer of Panacos Pharmaceuticals, Inc. "We look forward to working with their team of experienced scientists in developing the next generation of HIV therapies."
About Evotec OAI AG
Evotec OAI has established itself as the partner of choice for drug discovery and development solutions for pharmaceutical and biotechnology companies worldwide, maintaining its leadership role through innovation and unmatched customer service.
The Company's business strategy is clearly focussed on drug discovery. It has established the most comprehensive technology platform and skills that integrate its world-class biology and chemistry capabilities. Evotec OAI leverages this discovery engine in providing assay development and screening through to compound optimisation and drug manufacturing services to a broad and well-established network of customers. In addition, the Company engages in selected discovery programmes itself to develop drug candidates for early out-licensing. Evotec OAI's instrument and technology business is now successfully handled by its affiliate, Evotec Technologies.
With over 600 people in Hamburg, Germany and Oxfordshire, UK, Evotec OAI is dedicated to returning value to its shareholders and employees through a sustainable business strategy that balances short-term and long-term revenue opportunities.
About Panacos Pharmaceuticals, Inc. 
Panacos Pharmaceuticals is engaged in the discovery and development of small molecule, orally available drugs for the treatment of HIV and other major human viral diseases.  The Company's proprietary discovery technologies focus on novel targets in the virus life cycle, including virus fusion and virus maturation, the first and last steps of viral infection. 

Contact: Anne Hennecke, Investor Relations & Corporate Communications, phone: +49-40-56081-286, anne.hennecke@evotecoai.com
Contact: Anne Hennecke, Investor Relations & Corporate Communications, phone: +49-40-56081-286, anne.hennecke@evotecoai.com